OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)
Claudia Proto, M. Ganzinelli, Sara Manglaviti, et al.
Annals of Oncology (2024) Vol. 35, Iss. 9, pp. 817-826
Open Access | Times Cited: 8
Claudia Proto, M. Ganzinelli, Sara Manglaviti, et al.
Annals of Oncology (2024) Vol. 35, Iss. 9, pp. 817-826
Open Access | Times Cited: 8
Showing 8 citing articles:
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME)
Chiara Catania, Sara Manglaviti, Paolo Andrea Zucali, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 239-239
Open Access
Chiara Catania, Sara Manglaviti, Paolo Andrea Zucali, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 239-239
Open Access
First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma
Tommaso De Pas, Giuseppe Giaccone, Chiara Catania, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 68-68
Open Access
Tommaso De Pas, Giuseppe Giaccone, Chiara Catania, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 68-68
Open Access
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
Takehito Shukuya, Tetsuhiko Asao, Yasushi Goto, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 3, pp. 331-342
Closed Access
Takehito Shukuya, Tetsuhiko Asao, Yasushi Goto, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 3, pp. 331-342
Closed Access
Thymic malignancies: role of immunotherapy and novel approaches
Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
S1701, A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma
Anne S. Tsao, Ming-Hui Hsieh, Marianna Koczywas, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 12, pp. 100738-100738
Open Access
Anne S. Tsao, Ming-Hui Hsieh, Marianna Koczywas, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 12, pp. 100738-100738
Open Access
Prospects for Thymic Carcinoma Treatment
Yusuke Okuma
Haigan (2024) Vol. 64, Iss. 6, pp. 821-827
Open Access
Yusuke Okuma
Haigan (2024) Vol. 64, Iss. 6, pp. 821-827
Open Access
Systemic Treatment for Thymic Epithelial Tumor
Takehito Shukuya, Shinya Fujioka, Shoko Shimamura, et al.
Haigan (2024) Vol. 64, Iss. 6, pp. 839-847
Open Access
Takehito Shukuya, Shinya Fujioka, Shoko Shimamura, et al.
Haigan (2024) Vol. 64, Iss. 6, pp. 839-847
Open Access
Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas
Serena Barachini, Eleonora Pardini, Irene Sofia Burzi, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 166-166
Open Access
Serena Barachini, Eleonora Pardini, Irene Sofia Burzi, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 166-166
Open Access
